This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Antonio Marchini - Innovator in Cancer Research
Introduction
Antonio Marchini is a notable inventor based in Luxembourg, LU. He is currently affiliated with the Deutsches Krebsforschungszentrum - Stiftung Des Öffentlichen Rechts / Universität Heidelberg. His work primarily focuses on the development of innovative therapies for cancer treatment. Although he has not yet been granted any patents, his research contributions are significant in the field of oncology.
Latest Patent Applications
Antonio Marchini has been involved in several latest patent applications that showcase his innovative approach to cancer therapy. One of his applications is titled "Novel oncolytic parvoviruses with enhanced cargo capacity, stable shRNA expression cassette and novel immunogenic properties." This application describes engineered oncolytic protoparvoviruses designed for use in cancer therapy. These engineered viruses contain specific deletions in the untranslated region and a silencer sequence that remains stably integrated into the viral genome during extensive virus propagation. The novel viruses are intended for silencing relevant cancer-related genes, providing a new anticancer mechanism of action.
Another significant application is "Method for predicting the clinical response of oncolytic parvovirus H1 (H-1PV) treatment in a patient suspected of suffering from cancer by measuring the expression levels of laminins and/or galectins as biomarkers in a patient's sample." This invention focuses on the use of laminins and/or galectins as biomarkers to predict the outcome of treatment with oncolytic parvovirus H1 (H-1 PV) in cancer patients.
Conclusion
Antonio Marchini's innovative research in cancer therapy highlights his commitment to advancing medical science. His latest patent applications reflect his dedication to finding effective treatments for cancer patients.